Contrasting Entera Bio (ENTX) & The Competition

Entera Bio (NASDAQ:ENTX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Entera Bio to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Entera Bio and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1	0	4	1	2.83
Entera Bio Competitors	9869	15279	45589	1598	2.54

Entera Bio currently has a consensus price target of $9.60, suggesting a potential upside of 198.14%. As a group, “Biotechnology” companies have a potential upside of 120.39%. Given Entera Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Entera Bio is more favorable than its rivals.

Earnings & Valuation

This table compares Entera Bio and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Entera Bio	$40,000.00	-$11.44 million	-8.26
Entera Bio Competitors	$742.43 million	$12.94 million	-19.26

Entera Bio’s rivals have higher revenue and earnings than Entera Bio. Entera Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.7% of Entera Bio shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Entera Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-38.55%	-36.15%
Entera Bio Competitors	-12,323.33%	-195.38%	-30.39%

Volatility and Risk

Entera Bio has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Entera Bio’s rivals have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Summary

Entera Bio beats its rivals on 8 of the 13 factors compared.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.